Novo Nordisk A/S - Share repurchase programme
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 1 July 2019 – On 7 May 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 1 February 2019.
Under the programme initiated 7 May 2019, Novo Nordisk will repurchase B shares for an amount up to DKK 2.7 billion in the period from 8 May 2019 to 7 August 2019.
Since the announcement as of 24 June 2019, the following transactions have been made under the programme:
|Accumulated, last announcement||3,843,000||1,255,256,544|
|24 June 2019||125,000||332.94||41,617,055|
|25 June 2019||125,000||334.92||41,865,163|
|26 June 2019||125,000||336.72||42,089,417|
|27 June 2019||125,000||333.22||41,652,206|
|28 June 2019||125,000||334.52||41,815,478|
|Accumulated under the programme||4,468,000||1,464,295,863|
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 26,811,143 B shares of DKK 0.20, corresponding to 1.1% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,400,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 1 February 2019. As of 28 June 2019, Novo Nordisk has since 1 February 2019 repurchased a total of 19,644,504 B shares at an average share price of DKK 325.75 per B share equal to a transaction value of DKK 6,399,249,464.
|Anne Margrethe Hauge||+45 4442 firstname.lastname@example.org|
|Ken Inchausti (US)||+1 609 240 email@example.com|
|Peter Hugreffe Ankersen||+45 3075 firstname.lastname@example.org|
|Valdemar Borum Svarrer||+45 3079 email@example.com|
|Ann Søndermølle Rendbæk||+45 3075 firstname.lastname@example.org|
|Kristoffer Due Berg (US)||+1 609 235 email@example.com|
Company announcement No 39/2019
Upcoming Life Sciences Events
- September 2019
- Dusseldorf: 5th Annual Pre-Filled Syringes & Injectables Summit
- Munich: The Biotech & Pharma Summit: Drug Delivery & Formulation
- Brussels: The Pharma Forecasting Course